3rd Annual Pharmacovigilance and Risk Management Strategies - Home - International Conferences

We would like to thank our partners and sponsors for supporting us and the whole event, our speakers and advisers for contributing with their knowledge, experience and strategies, and all delegates for finding the time to join us in Madrid. We are delighted that you chose to attend the 3rd Annual Pharmacovigilance and Risk Management Strategies and we had the chance to meet you there and talk to you.

If you have any further questions or you are just eager to learn more about our upcoming events, do not hesitate to contact us. We would also appreciate your comments and suggestions that could help us improve our future conferences.

testimonials:

“Thank you very much for inviting me to the meeting, it was very usefull and well organized.”
Pharmacovigilance & Medical Information Associate, Abbott, Spain

“Thank you for organizing such an intersting and useful event, all the presentations lived up to my expectations!”
Head of Pharmacovigilance, Tha Dutch Medicines Evaluation Board, Netherlands

“It was a great pleasure being with you and attend the meeting. I think you succeeded in putting together an interesting program, and your work was appreciated by the audience.”
Sabine Straus, Head of Pharmacovigilance, the Dutch Medicines Evaluation Board, Netherlands

“I apprecitated highly qualified and experienced speakers from broad backgrounds.”
Teresa Martinez, Drug Safety Specialist, Roche

“Well organised event. I was happy to participate also from a professional point of view as the speakers and topics covered were high-level and comprehensive. Excellent event.”
Sanne Lassen, Senior Pharmacovigilance Specialist, Amgros

With the promise to be the biggest change to the regulation of human medicines since mid-1990’s, the European Union has redefined the practice of Pharmacovigilance by new legislation taking effect from July 2012. By managing risk proactively, avoiding administrative burdens, and providing for a greater connection between safety assessments and regulatory action, the new set of rules aims for improved public health in general and greater patient safety in particular.

Following up on two very successful events in January 2011 & 2012, Fleming Europe is proud to introduce to you the 3rd Annual Pharmacovigilance & Risk Management Strategies conference. This 2-day event will bring together expert minds from the industry, regulatory authorities and government to examine the Pharmacovigilance areas of key concern:

Recent developments and insights into new features and key changes introduced by the new PV legislation and its implementation (RMPs, safety reporting, PASS/PAES, etc.)
Overview and implications of the ICH E2C (R2) guideline
PV developments outside the ICH region
Creation of a successful and cost-effective PV system in the frame of the new legislation
Creation of safety data exchange agreements
Effectiveness of risk minimisation and establish monitoring system
PV in special products & populations (vaccines & elderly)